Innovation Spotlight Stages

Better Knowledge, Better Care: Precision Medicine for any Cancer, any Assay, on your Platform
Hosted by: QIAGEN

Speaker(s): TBD

QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present a lung cancer case study to show how QIAGEN Clinical Insight (QCI™) allows you to optimize and scale your pipeline for the clinical interpretation of genetic variants—from sequence data to report sign-off—without sacrificing accuracy or utility. QCI Interpret is a flexible clinical decision support suite that is compatible with any NGS platform, running any assay, targeting somatic, hereditary, hematological or childhood cancers.

Technologists for the Next Generation

Hosted by: AMP

Speakers: Technologist Representatives from The AMP Program Committee and The AMP Training & Education Committee

The goal of this presentation is to you progress in your career by:

• Providing resources for Continuing Education and improvement.
• Outlining paths for Molecular certification.
• Describing opportunities and paths for advancement.

Meet the Authors: “Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology”

Hosted by: AMP

Authors: Rebecca F. McClure, Mark D. Ewalt, Jennifer Crow, Robyn L. Temple-Smolkin, Mrudula Pullambhatla, Rachel Sargent, and Annette S. Kim.

To address the clinical relevance of small DNA variants in chronic myeloid neoplasms (CMNs), an AMP Working Group comprehensively reviewed published literature, summarized key findings that support clinical utility, and defined critical gene inclusions for high-throughput sequencing testing panels. This new manuscript appears in the November 2018 edition of JMD. Don’t miss a great opportunity to talk to the authors and ask questions.

Limitless - Premium Content. Premium Performance

A preview of Illumina’s TruSight Oncology 500: a comprehensive panel for tumor profiling of multiple DNA and RNA biomarkers, including TMB and MSI.

Hosted by: Illumina

Speaker: Ali Kuraishy – Sr. Product Manager, Oncology

During this talk, we will preview the TSO500 panel, which enables comprehensive profiling of current and emerging biomarkers across multiple tumor types. Learn how TSO500 gene content is aligned with key guidelines and clinical trials, and the panel coverage of relevant DNA and RNA variants, including small variants, fusions, splice variants, TMB and MSI. We will also discuss the importance of TMB as a biomarker, key requirements for a proper TMB evaluation, and what makes TSO500 a premium TMB assay.

Meet the Coding, Coverage, and Reimbursement Experts

Hosted by: AMP

Speakers: Samuel K. Caughron, MD; MAWD Pathology; North Kansas City, MO; Chair, EAC
Pranil Chandra, DO; PathGroup, Brentwood, TN; EAC Vice-Chair of Coverage Subcommittee
Anthony Sireci, MD; Loxo Oncology, Inc., Stamford CT; EAC Vice-Chair of New Codes and Pricing Subcommittee

AMP invites you to meet the Chair and Vice-Chairs of the AMP Economic Affairs Committee. During this thirty minute session, attendees will have the opportunity to ask questions and discuss topics on coding, coverage, and reimbursement of molecular diagnostic procedures and learn ways you can assist the EAC in its efforts. 

Testing Methods for Genomic Alterations, Including NTRK Gene Fusions    

Hosted by: Bayer and Loxo Oncology  

Speaker: John Longshore, PhD, FACMG, Carolinas Pathology Group

A tumor’s underlying genomic profile has become increasingly important in oncology. Genomic alterations, such as NTRK gene fusions, are an ongoing area of focus.  This session will cover consequence of NTRK gene fusions, the frequency of NTRK gene fusions across many tumor types, and provide an overview of detecting NTRK gene fusions in cancer.

QIAstat-Dx – The Next Generation of Syndromic Insights

Hosted by: QIAGEN

Speaker(s): TBD

Syndromic testing helps reduce diagnostic uncertainty and improve clinical decision making by providing insights that are more accurate, comprehensive, and actionable for real-time decisions. QIAstat-Dx® is the next generation of syndromic insights you have been waiting for. Powered by proven QIAGEN sample and assay technologies, you can now confidently provide clinical insights to patients with the highest level of versatility. The QIAstat-Dx is not currently available in the US.

Meet the Authors: “Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists"

Hosted by: AMP

Authors: Somak Roy, Christopher Coldren, Arivarasan Karunamurthy, Nefize S. Kip, Eric W. Klee, Stephen E. Lincoln, Annette Leon, Mrudula Pullambhatla, Robyn L. Temple-Smolkin, Karl V. Voelkerding (CAP), Chen Wang (AMIA), and Alexis B. Carter

The Association of Molecular Pathology, with organizational representation from the College of American Pathologists and the American Medical Informatics Association, has developed and published a set of 17 best practice consensus recommendations for the validation of clinical NGS bioinformatics pipelines. This manuscript appears in the January 2018 edition of JMD. Don’t miss a great opportunity to talk to the authors and ask questions.

AMP Certificate Courses    

Hosted by: AMP

Speakers: Jennifer Dunlap MD and Rashmi Goswami MD, PhD

AMP certificate programs are self-paced thematically bundled webinars designed to help you develop knowledge and skills needed for success in molecular pathology and diagnostics. Join us at the Innovation Stage where we’ll showcase two NEW AMPED^TM Certificate Programs:

1. The 2016 World Health Organization (WHO) Updates in Hematologic Malignancies.

2. Circulating Tumor DNA Testing: Advances, Challenges, and Applications.

Attendees will receive a coupon code for the AMP Certificate Program being presented.

NEBNext Direct: Moving Beyond Amplicon Sequencing for focused NGS Panels  

Hosted by: New England Biosciences

Speaker(s): TBD

Efficient utilization of targeted gene panels is challenged by high costs, long turnaround times, and difficulties in panel design. Furthermore, inherent issues with amplification-based enrichment include low uniformity of target coverage, and challenges when modifying content of a given panel. NEBNext Direct Custom Ready Panels employ a novel, hybridization-based approach to selectively enrich nucleic acid targets in a highly specific and uniform manner. We have optimized probes specific to the full exon content of ~850 human genes associated with a variety of disease areas. These can be combined as needed to allow rapid turnaround of specific custom gene subsets.

Meet the Authors: “Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology”    

Hosted by: AMP

Authors: Victoria M. Pratt, Andria L. Del Tredici, Houda Hachad, Yuan Ji, Lisa V. Kalman, Stuart A. Scott, Karen E. Weck

The Association of Molecular Pathology has developed and published a manuscript defining key attributes of CYP2C19 alleles and describes a recommended minimum set of variants that should be included in clinical pharmacogenomic genotyping assays. This manuscript appears in the May 2018 edition of JMD. Don’t miss a great opportunity to talk to the authors and ask questions.